Kishori

ABSTRACTVesicular systems provide large opportunities for the transdermal delivery of therapeutics. The present study was designed to investigate the potential of a novel class of vesicular system ‘proniosome’ as a carrier for transdermal delivery of telavancin. Proniosome formulations were prepared by co-acervation phase separation method. The developed system was characterized for drug release, zeta potential, particle size analysis and kinetics. Span 60 was the most appropriate surfactant, and yielded vesicle size and percentage encapsulation ef?ciency respectively. The in vitro telavancin proniosomes formulations exhibited a sustained release for 7 hrs. Zeta potential was found to be -32.7 mv which indicates the stability of the formulation. The proniosomes F6 formulation shows entrapment efficiency of 92.7%. From the diffusion study it was found that formulation F6 shows the highest drug permeation. F1 followed zero order release kinetic profile; F2 was first order release kinetic profile and for F3 to F7 followed Peppa’s model drug release kinetic profile. Formulations stored at refrigeration condition (8±2 °C) showed a higher drug entrapment when compared to the formulations stored at accelerated condition (30±2 0C) at (65±5%RH) after a period of 4 weeks. Keywords: Proniosomes, Telavancin, In vitro drug release and release kinetics

ABSTRACTDrug therapeutic effectiveness depends upon the drug molecules solubility and the bioavailability of drug molecules. After oral administration of drug to give pharmacological response, solubility is crucial parameter for obtaining desired concentration of drug molecule in systemic circulation. In current scenario about 40% of the newly developed drug molecules is poorly water soluble. With rate of dissolution and pharmacokinetic parameters like, absorption, distribution and excretion of drug molecules depend upon its solubility. Depending upon solubility and permeability, drugs are classified into four basic classes of the biopharmaceutical classification system (BCS) classification. The problem of poor solubility are faced in the Class II and Class IV of the biopharmaceutical classification system which comprises of novel generation of most all category of drugs like NSAIDs like Zaltoprofen,; anti-diabetics Gliclazide; newer calcium channel blockers like Nimodipine,. Till date various methods of ameliorating the solubility has been discovered and utilized successfully to enhance the solubility. This review highlights briefly on information about important approaches of novel solubility enhancement techniques.Keywords: Solubility enhancement, Cryo-technology, Sono-crstallization